Consolidated Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7311816

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-445,993,000 JPY
-362,953,000 JPY
Depreciation
17,602,000 JPY
15,398,000 JPY
Interest expenses
4,494,000 JPY
4,987,000 JPY
Foreign exchange losses (gains)
JPY
0 JPY
Decrease (increase) in trade receivables
13,248,000 JPY
12,414,000 JPY
Subtotal
-395,726,000 JPY
-339,024,000 JPY
Income taxes paid
-2,542,000 JPY
-2,441,000 JPY
Decrease (increase) in inventories
-3,412,000 JPY
-615,000 JPY
Increase (decrease) in trade payables
2,302,000 JPY
1,187,000 JPY
Net cash provided by (used in) operating activities
-371,740,000 JPY
-315,940,000 JPY
Other, net
153,000 JPY
-18,939,000 JPY
Interest paid
-4,523,000 JPY
-4,758,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,796,000 JPY
-11,347,000 JPY
Net cash provided by (used in) investing activities
-7,821,000 JPY
-11,347,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
3,430,000 JPY
5,450,000 JPY
Net increase (decrease) in short-term borrowings
-104,789,000 JPY
-4,736,000 JPY
Repayments of long-term borrowings
-9,000,000 JPY
-54,132,000 JPY
Net cash provided by (used in) financing activities
-108,809,000 JPY
-53,418,000 JPY
Net increase (decrease) in cash and cash equivalents
-488,370,000 JPY
-380,706,000 JPY
Cash and cash equivalents
2,385,402,000 JPY
2,873,773,000 JPY
3,056,601,000 JPY
3,437,307,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.